- Home
- SUPN vs NVCR Comparison
SUPN vs NVCR Comparison
Compare SUPN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- NVCR
- Stock Information
- Founded
- SUPN 2005
- NVCR 2000
- Country
- SUPN United States
- NVCR Switzerland
- Employees
- SUPN N/A
- NVCR N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- SUPN Health Care
- NVCR Health Care
- Exchange
- SUPN Nasdaq
- NVCR Nasdaq
- Market Cap
- SUPN 2.6B
- NVCR 1.4B
- IPO Year
- SUPN 2012
- NVCR 2015
- Fundamental
- Price
- SUPN $44.51
- NVCR $12.90
- Analyst Decision
- SUPN Buy
- NVCR Buy
- Analyst Count
- SUPN 2
- NVCR 7
- Target Price
- SUPN $43.00
- NVCR $28.79
- AVG Volume (30 Days)
- SUPN 631.6K
- NVCR 1.3M
- Earning Date
- SUPN 11-03-2025
- NVCR 10-29-2025
- Dividend Yield
- SUPN N/A
- NVCR N/A
- EPS Growth
- SUPN 1411.53
- NVCR N/A
- EPS
- SUPN 1.14
- NVCR N/A
- Revenue
- SUPN $665,125,000.00
- NVCR $630,160,000.00
- Revenue This Year
- SUPN $4.84
- NVCR $6.68
- Revenue Next Year
- SUPN $17.69
- NVCR $7.01
- P/E Ratio
- SUPN $38.46
- NVCR N/A
- Revenue Growth
- SUPN 5.55
- NVCR 14.58
- 52 Week Low
- SUPN $29.16
- NVCR $10.87
- 52 Week High
- SUPN $46.79
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SUPN 52.39
- NVCR 55.06
- Support Level
- SUPN N/A
- NVCR $12.08
- Resistance Level
- SUPN $46.72
- NVCR $12.83
- Average True Range (ATR)
- SUPN 1.00
- NVCR 0.56
- MACD
- SUPN -2.10
- NVCR 0.16
- Stochastic Oscillator
- SUPN 95.58
- NVCR 61.08
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.